Address
Pfizer Inc
235 East 42nd Street
150/39/18
New York, NY 10017
United States
Phone
Website
Business classification
VCID: 4229
Profile
Corporate information
Official name
Pfizer Incorporated
Registration country
Investment activity status
Active investor
Team
Current employees
![[node:title] photo](/sites/default/files/styles/icon/public/default_images/icon-person.png?itok=8SSzz6Wf "[node:title] photo"){kind=icon}
|
Barbara J Dalton |
Investments
Selected investments
| Company | Country | Date | Notes | ||
|---|---|---|---|---|---|
|
Phoenix Venture Partners II LP Venture capital fund focused on advanced materials startups. |
United States | 27 Mar 2017 | Fund Closing Initial investment. Round participant. Active |
|
|
Medivation Inc |
United States | 22 Aug 2016 | Acquisition USD 14,000,000,000 (USD 14,000,000,000) deal size. Active |
|
|
Anacor Pharmaceuticals Inc |
United States | 1 May 2016 | Acquisition USD 5,200,000,000 (USD 5,200,000,000) deal size. Initial investment. Led the investment round. Active |
|
|
Icagen Inc Biopharmaceutical company developing small molecule therapeutics that target ion channels for treatment of a variety of diseases. |
United States | 20 Jul 2011 | Acquisition USD 56,000,000 (USD 56,000,000) deal size. |
|
|
|
DVS Sciences Inc An analytical instrument and reagents company founded in Toronto |
United States | 1 Jul 2011 | Series A |
|
|
|
Neuronetics Inc |
United States | 1 May 2011 | Series E |
|
|
|
King Pharmaceuticals |
12 Oct 2010 | Acquisition USD 3,600,000,000 (USD 3,600,000,000) deal size. Initial investment. Led the investment round. Active |
||
|
|
FoldRx Pharmaceuticals Inc |
United States | 1 Sep 2010 | Acquisition |
|
|
|
TetraLogic Pharmaceuticals A leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. |
United States | 1 Sep 2010 | Series C |
|
|
|
Avid Radiopharmaceuticals Inc |
United States | 1 Jan 2006 1 May 2007 1 May 2009 |
Series D Active |
|
|
Wyeth Pharmaceuticals |
23 Jan 2009 | Acquisition USD 68,000,000,000 (USD 68,000,000,000) deal size. Initial investment. Round participant. Active |
||
|
|
Serenex Inc Oncology-focused drug development company |
United States | 3 Mar 2008 | Acquisition |
|
|
|
BioRexis Pharmaceutical Corp |
United States | 1 Feb 2007 | Acquisition |
|
|
|
Vicuron Pharmaceuticals Inc |
United States | 16 Jun 2005 | Acquisition USD 1,900,000,000 (USD 1,900,000,000) deal size. |
|
|
|
IDUN Pharmaceuticals Inc |
United States | 24 Feb 2005 | Acquisition |
|
|
|
Esperion Therapeutics Inc |
United States | N/A |
||
|
|
Coley Pharmaceutical Group Inc |
United States | N/A |
||
|
|
Excaliard Pharmaceuticals Inc |
United States | N/A |
